Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DI4SM3
|
|||
| Drug Name |
MT-1621
|
|||
| Drug Type |
Deoxynucleoside
|
|||
| Indication | Thymidine kinase 2 deficiency [ICD-11: 5C55.1 ] | Phase 3 | [1] | |
| Company |
Modis Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thymidine kinase 2 (Mt-TK2) | Target Info | Replacement | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04581733) A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Modis Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.